U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301320) titled 'Epetraborole in Patients With Mycobacterium Abscessus Lung Disease' on Dec. 22.
Brief Summary: This double-blind, randomized, placebo-controlled, parallel-group, multicenter, prospective, investigator-initiated trial will evaluate epetraborole (EBO) monotherapy in the treatment of adults with Mycobacterium abscessus complex (MABc) Lung Disease (LD) of mild to moderate severity. For this study, two EBO oral dose regimens will be studied in patients with MABc-LD, each compared to a placebo group (ie, 4 treatment groups): 500 mg daily and 750 mg daily. Detailed inclusion and exclusion criteria attempt to identify only those patients wh...